Compare Fresenius Kabi Onco. with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs NOVARTIS - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. NOVARTIS FRESENIUS KABI ONCO./
NOVARTIS
 
P/E (TTM) x 22.1 1,959.2 1.1% View Chart
P/BV x 3.1 26.0 12.0% View Chart
Dividend Yield % 0.0 1.7 -  

Financials

 FRESENIUS KABI ONCO.   NOVARTIS
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
NOVARTIS
Mar-19
FRESENIUS KABI ONCO./
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs176980 18.0%   
Low Rs79600 13.1%   
Sales per share (Unadj.) Rs37.7198.7 19.0%  
Earnings per share (Unadj.) Rs5.121.0 24.3%  
Cash flow per share (Unadj.) Rs6.722.3 30.2%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs42.5307.5 13.8%  
Shares outstanding (eoy) m158.2324.69 640.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.0 84.9%   
Avg P/E ratio x25.037.7 66.3%  
P/CF ratio (eoy) x18.935.5 53.3%  
Price / Book Value ratio x3.02.6 116.4%  
Dividend payout %047.7 0.0%   
Avg Mkt Cap Rs m20,13519,508 103.2%   
No. of employees `0001.20.6 198.3%   
Total wages/salary Rs m7031,171 60.0%   
Avg. sales/employee Rs Th5,176.28,445.4 61.3%   
Avg. wages/employee Rs Th610.42,015.7 30.3%   
Avg. net profit/employee Rs Th699.6891.0 78.5%   
INCOME DATA
Net Sales Rs m5,9634,907 121.5%  
Other income Rs m18783 2.3%   
Total revenues Rs m5,9815,689 105.1%   
Gross profit Rs m1,430123 1,164.6%  
Depreciation Rs m25832 811.0%   
Interest Rs m-2616 -163.5%   
Profit before tax Rs m1,216858 141.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342340 100.6%   
Profit after tax Rs m806518 155.7%  
Gross profit margin %24.02.5 958.3%  
Effective tax rate %28.139.6 71.0%   
Net profit margin %13.510.6 128.1%  
BALANCE SHEET DATA
Current assets Rs m5,1028,055 63.3%   
Current liabilities Rs m2,3851,850 128.9%   
Net working cap to sales %45.6126.4 36.0%  
Current ratio x2.14.4 49.1%  
Inventory Days Days15045 333.3%  
Debtors Days Days11334 334.1%  
Net fixed assets Rs m5,148150 3,436.6%   
Share capital Rs m158123 128.2%   
"Free" reserves Rs m6,5567,469 87.8%   
Net worth Rs m6,7327,592 88.7%   
Long term debt Rs m9520-   
Total assets Rs m10,3889,824 105.7%  
Interest coverage x-45.854.9 -83.3%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.5 114.9%   
Return on assets %7.55.4 138.2%  
Return on equity %12.06.8 175.6%  
Return on capital %14.611.5 126.9%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29858 9,197.2%   
Fx outflow Rs m1,7721,326 133.6%   
Net fx Rs m3,525-1,269 -277.9%   
CASH FLOW
From Operations Rs m1,274-1,943 -65.6%  
From Investments Rs m-1,2042,742 -43.9%  
From Financial Activity Rs m-196-298 65.8%  
Net Cashflow Rs m-126501 -25.2%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 75.0 108.0%  
Indian inst/Mut Fund % 0.3 2.0 15.0%  
FIIs % 9.6 1.6 600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 21.5 42.3%  
Shareholders   42,599 41,647 102.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   NEULAND LABS  DR. REDDYS LAB  ABBOTT INDIA  ALEMBIC  PROCTER & GAMBLE HEALTH  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market(Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers(Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - STRIDES PHARMA SCIENCE COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS